
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem Inc. is seeing significant growth potential driven by strong physician enthusiasm and a notable reduction in treatment discontinuation rates compared to historical MEK inhibitors. The company’s late-stage candidate, VS-7375, stands out as a promising best-in-class option within the competitive KRAS G12D market, with positive data supporting its efficacy and potential for broader guideline inclusion. Additionally, the durable outcomes reported for AVMAPKI FAKZYNJA in LGSOC and improvements in median duration of response for KRAS wild-type patients enhance the prospects for upcoming label expansion and overall market position.
Bears say
Verastem Inc. has demonstrated limited progress in treatment efficacy, with the median progression-free survival (mPFS) remaining nearly unchanged in KRAS wild-type patients and a decline in KRAS-mutant patients, suggesting challenges in clinical outcomes compared to standard of care. The company has consistently incurred operating losses since its inception, indicating ongoing financial strain and a potentially prolonged path to profitability. Additionally, the risk of failure in achieving regulatory approval for its therapies, compounded by the complexities of KRAS mutation biology and its implications on treatment responsiveness, contributes to a negative outlook for Verastem's stock performance.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares